Relation of inflammation to vascular function in patients with coronary heart disease

Atherosclerosis

Volumn 149, Issue 2, 2000, Pages 403-411

  Sinisalo, J ^a   Paronen, J ^b   Mattila, K J ^a   Syrjala M ^c   Alfthan, G ^b   Palosuo, T ^b   Nieminen, M S ^a   Vaarala, O ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Antibodies to oxidized low density lipoprotein; C reactive protein; Coronary disease; Endothelium; Inflammation

Indexed keywords

ACETYLCHOLINE; C REACTIVE PROTEIN; CD8 ANTIGEN; GLUCOSE; INTERCELLULAR ADHESION MOLECULE 1; LIPOPROTEIN; N(G) METHYLARGININE; NITROPRUSSIDE SODIUM; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; ANGIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; ENDOTHELIUM; HUMAN; INFLAMMATION; PLETHYSMOGRAPHY; PRIORITY JOURNAL; T LYMPHOCYTE; VASODILATATION;

AGED; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PROGNOSIS; REFERENCE VALUES; REGRESSION ANALYSIS; RISK FACTORS; VASCULAR PATENCY; VASOCONSTRICTION; VASODILATION;

EID: 0034019846     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00333-0     Document Type: Article

References (54)

1. Ross R. Mechanisms of disease: atherosclerosis - an inflammatory disease. New Engl J Med. 340:1999;115-121.
2. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
3. Koenig W., Sund M., Frohlich M., Fischer H.-G., Lowel H., Doring A., Hutchinson W.L., Pepys M.B. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 to 1992. Circulation. 99:1999;237-242.
4. Ridker P., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New Engl J Med. 336:1997;973-979.
5. Haverkate F., Thompson S.G., Pyke S.D.M., Gallimore J.R., Pepys M.B. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 349:1997;462-466.
6. Neri Serneri G., Prisco D., Martini F., Gori A.M., Brunelli T., Poggesi L., Rostagno C., Gensini G.F., Abbate R. Acute T-cell activation is detectable in unstable angina. Circulation. 95:1997;1806-1812.
7. Mendall M., Patel P., Ballam L., Strachan D., Northfield T.C. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. Br Med J. 312:1996;1061-1065.
8. Vaarala O. Atheroclerosis in SLE and in Hughes syndrome. Lupus. 6:1997;489-490.
9. Holvoet P., Vanhaecke J., Janssens S., Van de Werf F., Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stabile coronary artery disease. Circulation. 98:1998;1487-1494.
10. Puurunen M., Mänttäri M., Manninen V., Alfthan G., Ehnholm C., Vaarala O., Aho K., Palosuo T. Antibodies to oxidized low-density lipoprotein predicting myocardial infarction. Arch Int Med. 154:1994;2605-2609.
11. Noll G. Pathogenesis of atherosclerosis: a possible relation to infection. Atherosclerosis. 140(Suppl 1):1998;S3-S9.
12. Bhagat K., Moss R., Collier J., Vallance P. Endothelial stunning followed a brief exposure to endotoxin - a mechanism to link infection and infarction. Cardiovasc Res. 32:1996;822-829.
13. Bhagat K., Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation. 96:1997;3042-3047.
14. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-809.
15. Sinisalo J., Mattila K., Nieminen M.S., Valtonen V., Syrjälä M., Sundberg S., Saikku P. The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production. J Antimicrob Chemother. 41:1998;85-92.
16. Sundberg S. Variation in plethysmograpically measured limb blood flow using two study designs. Clin Phys. 15:1995;199-206.
17. Whitney R. The measurement of volume changes in human limbs. J Phys (London). 121:1953;1-27.
18. Kerslake D. The effect of application of an arterial occlusion cuff to wrist on the blood flow in the human forearm. J Phys (London). 108:1949;451-457.
19. Smith R., Kruszyna H. Nitroprusside produces cyanide poisoning via reaction with haemoglobin. J Pharmacol Exp Ther. 191:1974;553-563.
20. Furchgott R. Role of endothelium in responses of vascular smooth muscle. Circ Res. 53:1983;557-563.
21. Hodgson J., Marshall J.J. Direct vasoconstriction and endothelium-dependent vasodilatation: mechanisms of acetylcholine effects on coronary flow and arterial diameter in patients with nonstenotic coronary arteries. Circulation. 79:1989;1043-1051.
22. Vallance P., Collier J., Moncada S. Effects of endothelium-derived nitric oxide on periferial arteriolar tone in man. Lancet. II:1989;997-1000.
23. Lüscher T., Noll G. Endothelium dysfunction in the coronary circulation. J Cardiovasc Pharmacol. 24(Suppl. 3):1994;S16-S26.
24. Friedwald W., Levy R.I., Frederickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
25. Vaarala O., Alfthan G., Jauhiainen M., Lerisalo-Repo M., Aho K., Palosuo T. Cross-reaction between antibodies to oxidized lipoprotein and to cardiolipin in systemic lupus eryhematosus. Lancet. 341:1993;923-925.
26. Palinski W., Rosenfeld M.E., Ylä-Herttuala S., Gurtner G.C., Socher S.S., Butler S.W., Parthasarathy S., Carew T.E., Steinberg D., Witztum J.L. Low-density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA. 86:1989;1372-1376.
27. Palinski W., Ylä-Herttuala S., Rosenfeld M.E., Butler S.W., Socher S.A., Parthasarathy S., Curtiss L.K., Witztum J.L. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low-density lipoprotein. Atherosclerosis. 10:1990;325-335.
28. Dixon W. BMDP Statistical Software Manual. 1988;University of California Press, Berkeley, CA.
29. Vallance P., Collier J., Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide link. Lancet. 349:1997;1391-1392.
30. Heinrich J., Schulte H., Schönfeld R., Kohler E., Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis on coronary and periferial arteries and those arteries supplying the brain. Thromb Haemost. 73:1995;374-379.
31. Luizzo G., Biasucci L.M., Gallimore J.R., Grillo R.L., Rebuzzi A.G., Pepys M.B., Maseri A. Prognostic value of C-reactive protein and plasma amyloid A protein in severe unstable angina. New Engl J Med. 331:1994;417-424.
32. Liuzzo G., Buffon A., Biasucci L., Gallimore J.R., Caligiuri G., Vitelli A., Altamura S., Ciliberto G., Rebuzzi A.G., Crea F., Pepys M.B., Maseri A. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation. 98:1998;2370-2376.
33. Dinarello C. Interleukin-1 and biologically related cytokines. Adv Immunol. 44:1989;153-205.
34. Le J., Vilcek J. Biology of disease: interleukin-6: a multifunctional cytokine regulating immune reactions and acute phase response. Lab Invest. 61:1989;588-602.
35. Brody J., Pickering N.J., Capuzzi D.M., Fink G.B., Can C.A., Gomez F. Interleukin-1α as a factor in occlusive vascular disease. Am J Clin Pathol. 97:1992;8-13.
36. Kanda T., Hirao Y., Oshima S., Yuasa K., Taniguchi K., Nagai R., Kobayashi I. Interleukin-8 as a sensitive marker of unstable coronary artery disease. Am J Cardiol. 77:1996;304-307.
37. Muhlestein J., Anderson J.L., Hammond E.H., Zhao L., Trehan S., Schwobe E.P., Carlquist J.F. Infection with Chlamydia pneumoniae accelerate the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 97:1998;633-636.
38. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Mäkelä PH, Huttunen JK, Valtonen V. Serological evidence of an association of a novel chlamydia TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988: 983-986.
39. Heitzer T., Ylä-Herttuala S., Luoma J., Kurz S., Münzel T., Just H., Olschewski M., Drexler H. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. Circulation. 93:1996;1343-1353.
40. Zeiher A., Drexler H., Saurbier B., Just H. Endothelium-mediated coronary blood flow in humans: effect of age, atherosclerosis, hypercholesterolemia and hypertension. J Clin Invest. 92:1993;652-662.
41. Zeiher A., Drexler H., Wollschlänger H., Just H. Modulation of coronary vasomotor tone in human. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation. 83:1991;391-401.
42. Elliott T., Cockcroft J.R., Groop P.-H., Ritter J.M. Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent diabetic patients: blunted vasoconstriction in patients with microalbuminuria. Clin Sci. 85:1993;687-693.
43. Liao J., Bettmann M.A., Sandor T., Tucer J.I., Coleman S.M., Creager M.A. Differential impairment of vasodilatator responsiveness of peripheral resistance and conduit vessels in human atherosclerosis. Circ Res. 68:1991;1027-1034.
44. Flavahan N. Atherosclerosis or lipoprotein-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation. 85(5):1992;1927-1938.
45. Galle J., Bassenge E., Busse R. Oxidized low-density lipoproteins potentate vasoconstrictions in various agonists by direct interaction with vascular smooth muscle. Circ Res. 66:1990;1287-1293.
46. Galle J., Bassenge E. Effects of native and oxidized low-density lipoproteins on endothelium-dependent and endothelium-independent vasomotion. Basic Res Cardiol. 86(Suppl 2):1991;127-142.
47. Myers P., Wright T.F., Tanner M.A., Ostlund R.E. The effects of native and oxidized LDL on EDRF bioactivity and nitric oxide production in vascular endothelium. J Lab Clin Med. 124:1994;672-683.
48. Chin J., Azhar S., Hoffman B.B. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest. 89:1992;10-18.
49. Wurster S., Wang P., Dean R.E., Chaudry I.H. Vascular smooth muscle contractile function is impaired during early and late stages of sepsis. J Surg Res. 56:1994;556-561.
50. Jonsson H., Nived O., Sturfelt G. Outcome in systemic lupus ertyhematosis: a prospective study of patients from a defined population. Medicine (Baltimore). 68:1989;141-150.
51. G-monomethyl-l-arginine of vasodilator effects of acetylcholine and methacholine in human forearm vasculature. Br J Pharmacol. 110:1993;736-738.
52. Lejemtel T., Katz S., Jondeau G., Solomon S. Critical analysis of methods for assessing regional blood flow and their reliability in clinical medicine. Chest. 101:1992;219S-222S.
53. Webb D. The pharmacology of human blood vessels in vivo. J Vasc Res. 32:1995;2-15.
54. Utriainen T., Malmström R., Mäkimattila S., Yki-Järvinen H. Methodological aspects, dose-response characteristics and causes of interindividual variation in insulin stimulation of limb blood flow in normal subjects. Diabetologia. 38:1995;555-564.